The Role of GM-CSF in the Treatment of Acute Myeloid Leukemia
After a first study showed that GM-CSF following chemotherapy effectively accelerated neutrophil recovery and reduced early mortality in high risk patients with AML, a second study was begun in which GM-CSF was applied preceeding chemotherapy and continuing until neutrophil recovery in the initial 5...
Gespeichert in:
| Veröffentlicht in: | Leukemia & lymphoma 1993, Vol.11 (S2), p.21-24 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 24 |
|---|---|
| container_issue | S2 |
| container_start_page | 21 |
| container_title | Leukemia & lymphoma |
| container_volume | 11 |
| creator | Büchner, T. Hiddemann, W. Wörmann, B. Rottmann, R. Maschmeyer, G. Ludwig, W. D. Zuhlsdorf, M. Buntkirchen, K. Sander, A. Aswald, J. Binder, I. Prisett, S. Sauerland, M. C. |
| description | After a first study showed that GM-CSF following chemotherapy effectively accelerated neutrophil recovery and reduced early mortality in high risk patients with AML, a second study was begun in which GM-CSF was applied preceeding chemotherapy and continuing until neutrophil recovery in the initial 5 chemotherapy courses for patients with newly diagnosed AML. The CR rate in patients of 16-75 (median 50) years was 75% in GM-CSF patients and 84% in controls. GM-CSF patients showed a trend to more frequent rapid blast clearance and fewer persistent leukemias and a significantly superior remission duration as of this update two-and-a-half years after the study started. It should be shown later by this study whether GM-CSF multiple course priming and longterm administration adds to the cure rate of patients with AML. |
| doi_str_mv | 10.3109/10428199309064257 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76258978</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76258978</sourcerecordid><originalsourceid>FETCH-LOGICAL-c401t-e8d99cffd8757ab740cfa581a64f8cd182562c3d569bed3b639ab163bb012b43</originalsourceid><addsrcrecordid>eNp9kFFLwzAUhYMoc05_gA9Cn3yrJmnaJqgPY7gpbAja95KmN6wzbWbSIvv3tmwIIvp0L_ec83E5CF0SfBMRLG4JZpQTISIscMJonB6hMcFUhJTh6HjYGQ17AztFZ95vMMaxSOgIjTihjFI-Rg_ZGoJXayCwOliswtnbPKiaoO2vmQPZ1tC0gzRVXQvBagfGVmWwhO4d6kqeoxMtjYeLw5ygbP6YzZ7C5cvieTZdhoph0obASyGU1iVP41QWKcNKy5gTmTDNVUk4jROqojJORAFlVCSRkAVJoqLAhBYsmqDrPXbr7EcHvs3ryiswRjZgO5-nCY25SHlvJHujctZ7BzrfuqqWbpcTnA-N5b8a6zNXB3hX1FB-Jw4V9fr9Xq8abV0tP60zZd7KnbFOO9moyg_ov_F3P-JrkKZdK-kg39jONX1t_zz3BSbsiT8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76258978</pqid></control><display><type>article</type><title>The Role of GM-CSF in the Treatment of Acute Myeloid Leukemia</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Taylor & Francis Journals Complete</source><creator>Büchner, T. ; Hiddemann, W. ; Wörmann, B. ; Rottmann, R. ; Maschmeyer, G. ; Ludwig, W. D. ; Zuhlsdorf, M. ; Buntkirchen, K. ; Sander, A. ; Aswald, J. ; Binder, I. ; Prisett, S. ; Sauerland, M. C.</creator><creatorcontrib>Büchner, T. ; Hiddemann, W. ; Wörmann, B. ; Rottmann, R. ; Maschmeyer, G. ; Ludwig, W. D. ; Zuhlsdorf, M. ; Buntkirchen, K. ; Sander, A. ; Aswald, J. ; Binder, I. ; Prisett, S. ; Sauerland, M. C.</creatorcontrib><description>After a first study showed that GM-CSF following chemotherapy effectively accelerated neutrophil recovery and reduced early mortality in high risk patients with AML, a second study was begun in which GM-CSF was applied preceeding chemotherapy and continuing until neutrophil recovery in the initial 5 chemotherapy courses for patients with newly diagnosed AML. The CR rate in patients of 16-75 (median 50) years was 75% in GM-CSF patients and 84% in controls. GM-CSF patients showed a trend to more frequent rapid blast clearance and fewer persistent leukemias and a significantly superior remission duration as of this update two-and-a-half years after the study started. It should be shown later by this study whether GM-CSF multiple course priming and longterm administration adds to the cure rate of patients with AML.</description><identifier>ISSN: 1042-8194</identifier><identifier>EISSN: 1029-2403</identifier><identifier>DOI: 10.3109/10428199309064257</identifier><identifier>PMID: 8124228</identifier><language>eng</language><publisher>United States: Informa UK Ltd</publisher><subject>acute myeloid leukemia ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; GM-CSF ; Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use ; Humans ; Leukemia, Myeloid, Acute - therapy ; Middle Aged</subject><ispartof>Leukemia & lymphoma, 1993, Vol.11 (S2), p.21-24</ispartof><rights>1993 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1993</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c401t-e8d99cffd8757ab740cfa581a64f8cd182562c3d569bed3b639ab163bb012b43</citedby><cites>FETCH-LOGICAL-c401t-e8d99cffd8757ab740cfa581a64f8cd182562c3d569bed3b639ab163bb012b43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/10428199309064257$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/10428199309064257$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,4022,27921,27922,27923,59645,59751,60434,60540,61219,61254,61400,61435</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8124228$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Büchner, T.</creatorcontrib><creatorcontrib>Hiddemann, W.</creatorcontrib><creatorcontrib>Wörmann, B.</creatorcontrib><creatorcontrib>Rottmann, R.</creatorcontrib><creatorcontrib>Maschmeyer, G.</creatorcontrib><creatorcontrib>Ludwig, W. D.</creatorcontrib><creatorcontrib>Zuhlsdorf, M.</creatorcontrib><creatorcontrib>Buntkirchen, K.</creatorcontrib><creatorcontrib>Sander, A.</creatorcontrib><creatorcontrib>Aswald, J.</creatorcontrib><creatorcontrib>Binder, I.</creatorcontrib><creatorcontrib>Prisett, S.</creatorcontrib><creatorcontrib>Sauerland, M. C.</creatorcontrib><title>The Role of GM-CSF in the Treatment of Acute Myeloid Leukemia</title><title>Leukemia & lymphoma</title><addtitle>Leuk Lymphoma</addtitle><description>After a first study showed that GM-CSF following chemotherapy effectively accelerated neutrophil recovery and reduced early mortality in high risk patients with AML, a second study was begun in which GM-CSF was applied preceeding chemotherapy and continuing until neutrophil recovery in the initial 5 chemotherapy courses for patients with newly diagnosed AML. The CR rate in patients of 16-75 (median 50) years was 75% in GM-CSF patients and 84% in controls. GM-CSF patients showed a trend to more frequent rapid blast clearance and fewer persistent leukemias and a significantly superior remission duration as of this update two-and-a-half years after the study started. It should be shown later by this study whether GM-CSF multiple course priming and longterm administration adds to the cure rate of patients with AML.</description><subject>acute myeloid leukemia</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>GM-CSF</subject><subject>Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use</subject><subject>Humans</subject><subject>Leukemia, Myeloid, Acute - therapy</subject><subject>Middle Aged</subject><issn>1042-8194</issn><issn>1029-2403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kFFLwzAUhYMoc05_gA9Cn3yrJmnaJqgPY7gpbAja95KmN6wzbWbSIvv3tmwIIvp0L_ec83E5CF0SfBMRLG4JZpQTISIscMJonB6hMcFUhJTh6HjYGQ17AztFZ95vMMaxSOgIjTihjFI-Rg_ZGoJXayCwOliswtnbPKiaoO2vmQPZ1tC0gzRVXQvBagfGVmWwhO4d6kqeoxMtjYeLw5ygbP6YzZ7C5cvieTZdhoph0obASyGU1iVP41QWKcNKy5gTmTDNVUk4jROqojJORAFlVCSRkAVJoqLAhBYsmqDrPXbr7EcHvs3ryiswRjZgO5-nCY25SHlvJHujctZ7BzrfuqqWbpcTnA-N5b8a6zNXB3hX1FB-Jw4V9fr9Xq8abV0tP60zZd7KnbFOO9moyg_ov_F3P-JrkKZdK-kg39jONX1t_zz3BSbsiT8</recordid><startdate>1993</startdate><enddate>1993</enddate><creator>Büchner, T.</creator><creator>Hiddemann, W.</creator><creator>Wörmann, B.</creator><creator>Rottmann, R.</creator><creator>Maschmeyer, G.</creator><creator>Ludwig, W. D.</creator><creator>Zuhlsdorf, M.</creator><creator>Buntkirchen, K.</creator><creator>Sander, A.</creator><creator>Aswald, J.</creator><creator>Binder, I.</creator><creator>Prisett, S.</creator><creator>Sauerland, M. C.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1993</creationdate><title>The Role of GM-CSF in the Treatment of Acute Myeloid Leukemia</title><author>Büchner, T. ; Hiddemann, W. ; Wörmann, B. ; Rottmann, R. ; Maschmeyer, G. ; Ludwig, W. D. ; Zuhlsdorf, M. ; Buntkirchen, K. ; Sander, A. ; Aswald, J. ; Binder, I. ; Prisett, S. ; Sauerland, M. C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c401t-e8d99cffd8757ab740cfa581a64f8cd182562c3d569bed3b639ab163bb012b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>acute myeloid leukemia</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>GM-CSF</topic><topic>Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use</topic><topic>Humans</topic><topic>Leukemia, Myeloid, Acute - therapy</topic><topic>Middle Aged</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Büchner, T.</creatorcontrib><creatorcontrib>Hiddemann, W.</creatorcontrib><creatorcontrib>Wörmann, B.</creatorcontrib><creatorcontrib>Rottmann, R.</creatorcontrib><creatorcontrib>Maschmeyer, G.</creatorcontrib><creatorcontrib>Ludwig, W. D.</creatorcontrib><creatorcontrib>Zuhlsdorf, M.</creatorcontrib><creatorcontrib>Buntkirchen, K.</creatorcontrib><creatorcontrib>Sander, A.</creatorcontrib><creatorcontrib>Aswald, J.</creatorcontrib><creatorcontrib>Binder, I.</creatorcontrib><creatorcontrib>Prisett, S.</creatorcontrib><creatorcontrib>Sauerland, M. C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia & lymphoma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Büchner, T.</au><au>Hiddemann, W.</au><au>Wörmann, B.</au><au>Rottmann, R.</au><au>Maschmeyer, G.</au><au>Ludwig, W. D.</au><au>Zuhlsdorf, M.</au><au>Buntkirchen, K.</au><au>Sander, A.</au><au>Aswald, J.</au><au>Binder, I.</au><au>Prisett, S.</au><au>Sauerland, M. C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Role of GM-CSF in the Treatment of Acute Myeloid Leukemia</atitle><jtitle>Leukemia & lymphoma</jtitle><addtitle>Leuk Lymphoma</addtitle><date>1993</date><risdate>1993</risdate><volume>11</volume><issue>S2</issue><spage>21</spage><epage>24</epage><pages>21-24</pages><issn>1042-8194</issn><eissn>1029-2403</eissn><abstract>After a first study showed that GM-CSF following chemotherapy effectively accelerated neutrophil recovery and reduced early mortality in high risk patients with AML, a second study was begun in which GM-CSF was applied preceeding chemotherapy and continuing until neutrophil recovery in the initial 5 chemotherapy courses for patients with newly diagnosed AML. The CR rate in patients of 16-75 (median 50) years was 75% in GM-CSF patients and 84% in controls. GM-CSF patients showed a trend to more frequent rapid blast clearance and fewer persistent leukemias and a significantly superior remission duration as of this update two-and-a-half years after the study started. It should be shown later by this study whether GM-CSF multiple course priming and longterm administration adds to the cure rate of patients with AML.</abstract><cop>United States</cop><pub>Informa UK Ltd</pub><pmid>8124228</pmid><doi>10.3109/10428199309064257</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1042-8194 |
| ispartof | Leukemia & lymphoma, 1993, Vol.11 (S2), p.21-24 |
| issn | 1042-8194 1029-2403 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76258978 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete |
| subjects | acute myeloid leukemia Adolescent Adult Aged Aged, 80 and over GM-CSF Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use Humans Leukemia, Myeloid, Acute - therapy Middle Aged |
| title | The Role of GM-CSF in the Treatment of Acute Myeloid Leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T09%3A01%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Role%20of%20GM-CSF%20in%20the%20Treatment%20of%20Acute%20Myeloid%20Leukemia&rft.jtitle=Leukemia%20&%20lymphoma&rft.au=B%C3%BCchner,%20T.&rft.date=1993&rft.volume=11&rft.issue=S2&rft.spage=21&rft.epage=24&rft.pages=21-24&rft.issn=1042-8194&rft.eissn=1029-2403&rft_id=info:doi/10.3109/10428199309064257&rft_dat=%3Cproquest_cross%3E76258978%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76258978&rft_id=info:pmid/8124228&rfr_iscdi=true |